Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Teva Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Doug who wrote (121)	11/13/1997 10:54:00 PM
From: Uncle Mikey	Respond to of 340

I read some of the details from NatWest in the WSJ. Mostly it was the lack of info on the MS drug. But read what Lehman has to say about this in a previous post on this thread. Even without the drug, Teva is cheap! The market has this one underpriced, that's my firm belief. Opportunity waiting for anyone willing to give it some time. WS wants immediate results, "long term" is two quarters from now. And rather than wait those two quarters they will put their money into something that's moving NOW!. Give this one two years and it will look like a very smart move.